Belantamab Mafodotin shows significant OS benefit, reducing the risk of death by 42% in multiple myeloma at or after first ...

Updated results from the DREAMM-7 trial support the use of belantamab mafodotin plus bortezomib and dexamethasone “as a potential new standard of care,” according to Vania Hungria, MD, PhD.

智通财经APP获悉，葛兰素史克(GSK.US)报告称，一项研究表明，其药物 belantamab mafodotin 能够将多发性骨髓瘤患者在首次复发时或复发后的死亡风险降低 42%。该研究正在评估 belantamab mafodotin 与 ...

A significant overall survival (OS) benefit with belantamab mafodotin (belantamab; Blenrep) in a phase III trial of relapsed ...

GSK (NYSE:GSK) reported that a study showed its drug belantamab mafodotin was able to reduce the risk of death by 42% in ...

GSK (GSK) reported a study showed its drug belantamab mafodotin was able to reduce the risk of death by 42% in certain ...

London: GSK plc has announced that the National Medical Products Administration (NMPA) of China has accepted for review a new ...

GSK今日宣布，其抗体偶联药物（ADC）Blenrep（belantamab mafodotin）在3期临床试验DREAMM-7的预定中期分析中获得了积极结果。该试验评估了Blenrep联合硼替佐 ...

The DREAMM-7 trial shows belantamab mafodotin combined with bortezomib and dexamethasone significantly improves overall ...

A trial has shown that belantamab mafodotin can reduce the risk of death by 42% in patients with relapsed or refractory ...

GSK (GSK) announced “statistically significant and clinically meaningful” overall survival results from a planned interim analysis of the ...

The DREAMM-7 trial showed belantamab mafodotin combination significantly improved overall survival in relapsed/refractory multiple myeloma compared to daratumumab-based therapy. The ...